Leith Abdulla, MD
Cardiovascular Disease · Olney, MDNPI 1861606782
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 95 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 26 manufacturers, the largest accounting for just 15.7% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $685, 8.3 times the $83 reported in 2019.
Across 95 payments — averaging $20.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$308
- Bayer$220
- Pfizer$111
- Boehringer Ingelheim$111
- Novo Nordisk$107
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$107
- plus $1K from 20 others
What the payments were for
- Food & beverage$1,965100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 13 | $308 |
| Bayer | 11 | $220 |
| Pfizer | 6 | $111 |
| Boehringer Ingelheim | 5 | $111 |
| Novo Nordisk | 5 | $107 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 8 | $107 |
| Exact Sciences | 2 | $106 |
| Esperion Therapeutics, Inc. | 5 | $102 |
| Novartis | 5 | $96 |
| Shield Therapeutics Inc | 4 | $81 |
| Actelion Pharmaceuticals US, Inc. | 4 | $78 |
| Merck | 4 | $72 |
| Amarin Pharma, Inc. | 4 | $67 |
| Lilly USA, LLC | 4 | $59 |
| Dexcom, Inc. | 1 | $50 |
| Philips North America LLC | 2 | $46 |
| Johnson & Johnson | 2 | $34 |
| E.r. Squibb & Sons, L.L.C. | 2 | $31 |
| Scpharmaceuticals Inc. | 1 | $31 |
| United Therapeutics Corporation | 1 | $29 |
| ARS Pharmaceuticals Operations, Inc. | 1 | $24 |
| Boston Scientific | 1 | $23 |
| Medicomp Inc | 1 | $22 |
| Heartflow, Inc. | 1 | $19 |
| AbbVie | 1 | $16 |
| Irhythm Technologies, Inc. | 1 | $15 |
How this compares
$1,965 in reported general payments places this provider in the 55th percentile of 507 cardiovascular disease providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other cardiovascular disease in Olney
- Robert GallinoOlney$15K
- Navin KapurBaltimore$1.5M
- Michael BlahaBaltimore$609K
- Sanjay RajagopalanBaltimore$521K
- Allen TaylorN Bethesda$456K
- David GoorayLargo$333K
- Erin MichosBaltimore$257K
- Seth MartinBaltimore$166K
- Erika FellerBaltimore$121K
- Mark HaigneyBethesda$121K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.